Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH- HAE: SAHARA Randomized Study  William R. Lumry, MD, Inmaculada Martinez-Saguer,

Published byJohan Therkildsen Modified over 5 years ago

Similar presentations

Presentation on theme: "Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH- HAE: SAHARA Randomized Study  William R. Lumry, MD, Inmaculada Martinez-Saguer,"— Presentation transcript:

1 Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH- HAE: SAHARA Randomized Study  William R. Lumry, MD, Inmaculada Martinez-Saguer, MD, William H. Yang, MD, Jonathan A. Bernstein, MD, Joshua Jacobs, MD, Dumitru Moldovan, MD, Marc A. Riedl, MD, MS, Douglas T. Johnston, DO, H. Henry Li, MD, Yongqiang Tang, PhD, Jennifer Schranz, MD, Peng Lu, MD, Moshe Vardi, MD, Henriette Farkas, MD P. Keith, W. Yang, M. Maurer, I. Martinez-Saguer, H. Farkas, A. Reshef, S. Kivity, D. Moldovan, T. Caballero, M. Guilarte, M.D. Hernandez, M.T. González-Quevedo, A. Banerji, J. Bernstein, A. Bewtra, T. Craig, S. Fineman, R. Gower, J. Jacobs, D. Johnston, J. Kashkin, H.H. Li, W.R. Lumry, M. Manning, D. McNeil, I. Melamed, N. Mumneh, T. Nickel, J. Panuto, D. Soteres, R. Tachdjian, J. Offenberger, J. Wedner William R. Lumry, MD, Inmaculada Martinez-Saguer, MD, William H. Yang, MD, Jonathan A. Bernstein, MD, Joshua Jacobs, MD, Dumitru Moldovan, MD, Marc A. Riedl, MD, MS, Douglas T. Johnston, DO, H. Henry Li, MD, Yongqiang Tang, PhD, Jennifer Schranz, MD, Peng Lu, MD, Moshe Vardi, MD, Henriette Farkas, MD P. Keith, W. Yang, M. Maurer, I. Martinez-Saguer, H. Farkas, A. Reshef, S. Kivity, D. Moldovan, T. Caballero, M. Guilarte, M.D. Hernandez, M.T. González-Quevedo, A. Banerji, J. Bernstein, A. Bewtra, T. Craig, S. Fineman, R. Gower, J. Jacobs, D. Johnston, J. Kashkin, H.H. Li, W.R. Lumry, M. Manning, D. McNeil, I. Melamed, N. Mumneh, T. Nickel, J. Panuto, D. Soteres, R. Tachdjian, J. Offenberger, J. Wedner  The Journal of Allergy and Clinical Immunology: In Practice  Volume 7, Issue 5, Pages e4 (May 2019) DOI: /j.jaip Copyright © 2019 The Authors Terms and Conditions

2 Figure 1 Normalized number of HAE attacks during treatment periods. Based on the full analysis set from the crossover sequences, consisting of all patients in the safety set who received ≥1 postbaseline (eg, randomization) primary efficacy assessment. CI, Confidence interval; HAE, hereditary angioedema; LS, least squares; NNA, normalized number of attacks; pdC1-INH, plasma-derived C1-INH; SD, standard deviation. †Reflects the entire study period. ‡Reflects the steady state period. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, e4DOI: ( /j.jaip ) Copyright © 2019 The Authors Terms and Conditions

3 Figure 2 Proportion of patients achieving ≥50%, ≥70%, ≥90, and 100% reduction in NNA during treatment periods relative to placebo periods, from day 1 and from day 15. Clinical response (≥50% reduction in NNA vs placebo) was achieved by 77.6% and 76.6% of patients from days 1 and 15, respectively. Based on the full analysis set from the crossover sequences with patients who had data in both treatment periods. The proportion of patients achieving a reduction in normalized number of attacks with C1-INH liquid versus placebo was statistically significant for each category of response (from day 1: ≥50%, P < .0001; ≥70%, P < .0001; ≥90%, P =. 0005; 100%, P = .0233; from day 15: ≥50%, P < .0001; ≥70%, P < .0001; ≥90%, P = .0002; 100%, P = .0058) relative to a predetermined efficacy threshold of 20%. Error bars represent 95% CI values. CI, Confidence interval; NNA, normalized number of attacks; pdC1-INH, plasma-derived C1-INH. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, e4DOI: ( /j.jaip ) Copyright © 2019 The Authors Terms and Conditions

4 Figure 3 Maximum attack severity. Based on the full analysis set from the crossover sequences; not restricted to patients who improved or who had data from both treatment periods. Percentages may not total 100 because of rounding. pdC1-INH, Plasma-derived C1-INH; SC, subcutaneous. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, e4DOI: ( /j.jaip ) Copyright © 2019 The Authors Terms and Conditions

5 Figure E1 Patient disposition. One patient receiving pdC1-INH liquid experienced 2 TEAEs that led to treatment withdrawal (nausea and headache). Both events were considered treatment related and occurred within 24 hours of administration. Two patients receiving placebo experienced 2 TEAEs leading to withdrawal (one had cardiac arrest and the other had an HAE attack). Neither event was considered treatment related. HAE, Hereditary angioedema; pdC1-INH, plasma-derived C1-INH; SC, subcutaneous. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, e4DOI: ( /j.jaip ) Copyright © 2019 The Authors Terms and Conditions

6 Figure E2 Occurrence of HAE attacks, attack severity, and use of on-demand medications. The height of vertical bars indicates the maximum attack severity of each dosing day, and the width indicates attack duration. The red dots indicate acute treatment. The horizontal lines indicate treatment duration. HAE, Hereditary angioedema. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, e4DOI: ( /j.jaip ) Copyright © 2019 The Authors Terms and Conditions

Download ppt "Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH- HAE: SAHARA Randomized Study  William R. Lumry, MD, Inmaculada Martinez-Saguer,"

Similar presentations

Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy  Henriette Farkas, MD, PhD, DSc, László Jakab, MD, György Temesszentandrási,

Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy  Henriette Farkas, MD, PhD, DSc, László Jakab, MD, György Temesszentandrási,
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients  Henriette Farkas, MD, PhD, DSc, Dorottya.

Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients  Henriette Farkas, MD, PhD, DSc, Dorottya.
Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks  Timothy J. Craig, MD, Robyn J. Levy,

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks  Timothy J. Craig, MD, Robyn J. Levy,
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema  William R. Lumry, MD, Timothy Craig,

Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema  William R. Lumry, MD, Timothy Craig,
Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data  Marc A. Riedl, MD, MS, Anette Bygum, MD, William Lumry, MD, Markus Magerl,

Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data  Marc A. Riedl, MD, MS, Anette Bygum, MD, William Lumry, MD, Markus Magerl,
Emergency Department Management of Hereditary Angioedema Attacks: Patient Perspectives  Iris M. Otani, MD, Sandra C. Christiansen, MD, Paula Busse, MD,

Emergency Department Management of Hereditary Angioedema Attacks: Patient Perspectives  Iris M. Otani, MD, Sandra C. Christiansen, MD, Paula Busse, MD,
Aleena Banerji, MD, Kimberly G. Blumenthal, MD, MSc, Kenneth H

Aleena Banerji, MD, Kimberly G. Blumenthal, MD, MSc, Kenneth H
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy  Thomas B. Casale, MD, Jonathan A. Bernstein,

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy  Thomas B. Casale, MD, Jonathan A. Bernstein,
Findings from an Online Survey Assessing the Burden and Management of Seasonal Allergic Rhinoconjunctivitis in US Patients  Eli O. Meltzer, MD, Judith.

Findings from an Online Survey Assessing the Burden and Management of Seasonal Allergic Rhinoconjunctivitis in US Patients  Eli O. Meltzer, MD, Judith.
Meta-analysis of randomized controlled trials on the efficacy and safety of ondansetron in preventing postanesthesia shivering  Min Li, Xiaolan Hu, Yuan.

Meta-analysis of randomized controlled trials on the efficacy and safety of ondansetron in preventing postanesthesia shivering  Min Li, Xiaolan Hu, Yuan.
Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor–Induced Upper Airway Angioedema  Richard Sinert, DO, Phillip Levy, MD, MPH,

Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor–Induced Upper Airway Angioedema  Richard Sinert, DO, Phillip Levy, MD, MPH,
Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents  James W. Baker, MD, Avner Reshef, MD, Dumitru Moldovan,

Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents  James W. Baker, MD, Avner Reshef, MD, Dumitru Moldovan,
Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks  Timothy J. Craig, MD, Robyn J. Levy,

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks  Timothy J. Craig, MD, Robyn J. Levy,
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical.

Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical.
Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility 

Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility 
Network Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass Products Have Comparable Efficacy  Harold Nelson, MD, Shannon Cartier, MSc,

Network Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass Products Have Comparable Efficacy  Harold Nelson, MD, Shannon Cartier, MSc,
Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds Through Immunotherapy  Joseph L. Baumert, PhD, Steve.

Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds Through Immunotherapy  Joseph L. Baumert, PhD, Steve.

Similar presentations

Ads by Google